NO20031673L - Behandling av kreft - Google Patents

Behandling av kreft

Info

Publication number
NO20031673L
NO20031673L NO20031673A NO20031673A NO20031673L NO 20031673 L NO20031673 L NO 20031673L NO 20031673 A NO20031673 A NO 20031673A NO 20031673 A NO20031673 A NO 20031673A NO 20031673 L NO20031673 L NO 20031673L
Authority
NO
Norway
Prior art keywords
cancer
treatment
aplidine
carnitine
useful
Prior art date
Application number
NO20031673A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031673D0 (no
Inventor
Lazaro Luis Lopez
Jose Maria Fernandez-Sousa
Jean-Pierre Armand
Eric Raymond
Original Assignee
Ruffles Graham Keith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0025044A external-priority patent/GB0025044D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Priority claimed from PCT/GB2000/004349 external-priority patent/WO2001035974A2/en
Priority claimed from GB0107373A external-priority patent/GB0107373D0/en
Priority claimed from PCT/GB2001/004555 external-priority patent/WO2002030441A2/en
Application filed by Ruffles Graham Keith filed Critical Ruffles Graham Keith
Publication of NO20031673D0 publication Critical patent/NO20031673D0/no
Publication of NO20031673L publication Critical patent/NO20031673L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
NO20031673A 2000-10-12 2003-04-11 Behandling av kreft NO20031673L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0025044A GB0025044D0 (en) 2000-10-12 2000-10-12 Toxicity protection
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers
GB0107373A GB0107373D0 (en) 2001-03-23 2001-03-23 Aplidine
PCT/GB2001/004555 WO2002030441A2 (en) 2000-10-12 2001-10-12 Treatment of cancers by aplidine in conjunction with a myoprotector

Publications (2)

Publication Number Publication Date
NO20031673D0 NO20031673D0 (no) 2003-04-11
NO20031673L true NO20031673L (no) 2003-06-12

Family

ID=27255931

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031673A NO20031673L (no) 2000-10-12 2003-04-11 Behandling av kreft

Country Status (14)

Country Link
US (1) US7507766B2 (cs)
JP (1) JP2010031043A (cs)
KR (1) KR20030038812A (cs)
CN (1) CN1479622A (cs)
AT (1) ATE299028T1 (cs)
BR (1) BR0114604A (cs)
CZ (1) CZ2003993A3 (cs)
ES (1) ES2243555T3 (cs)
HK (1) HK1054191A1 (cs)
IL (1) IL155273A0 (cs)
NO (1) NO20031673L (cs)
NZ (1) NZ525196A (cs)
PL (1) PL361179A1 (cs)
RU (1) RU2003113210A (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149488A0 (en) * 1999-11-15 2002-11-10 Pharma Mar Sa Pharmaceutical compositions containing aplidine
KR20060002778A (ko) * 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
US20090226465A1 (en) * 2005-10-31 2009-09-10 Jackson David Y Macrocyclic depsipeptide antibody-drug conjugates and methods
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5861439A (en) 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
EP0914116B1 (en) 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
AU3353897A (en) 1996-07-03 1998-02-02 Mckechnie Uk Limited Container
JP2001503746A (ja) 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
JP2001504814A (ja) 1996-10-24 2001-04-10 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニンＡのアミノＨｉｐ類似体の全合成
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
WO1998050048A1 (en) 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
DE69923322T2 (de) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
HK1046846A1 (zh) 1999-05-25 2003-01-30 Point Therapeutics, Inc. 包含boroproline的抗肿瘤复合物
IL149488A0 (en) 1999-11-15 2002-11-10 Pharma Mar Sa Pharmaceutical compositions containing aplidine
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU1305302A (en) 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
WO2002030441A2 (en) 2000-10-12 2002-04-18 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
KR20060002778A (ko) 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료

Also Published As

Publication number Publication date
CZ2003993A3 (cs) 2004-02-18
ATE299028T1 (de) 2005-07-15
NZ525196A (en) 2004-09-24
US20040010043A1 (en) 2004-01-15
ES2243555T3 (es) 2005-12-01
PL361179A1 (en) 2004-09-20
JP2010031043A (ja) 2010-02-12
BR0114604A (pt) 2003-10-14
NO20031673D0 (no) 2003-04-11
HK1054191A1 (zh) 2003-11-21
CN1479622A (zh) 2004-03-03
US7507766B2 (en) 2009-03-24
IL155273A0 (en) 2003-11-23
RU2003113210A (ru) 2004-11-27
KR20030038812A (ko) 2003-05-16

Similar Documents

Publication Publication Date Title
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
EP1478406A4 (en) COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
DE60329515D1 (de) Analoga und prodrugs von buprenorphin
TR200200118T2 (tr) Yeni bileşimler
EP1240280A4 (en) PROCESS FOR TREATING COAL
PT1235571E (pt) Utilizacao de melatonina para o tratamento da alopecia androgenetica e difusa do tipo feminino
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
NO994274L (no) Sammensetninger til Õ behandle tumörer inneholdende haibruskekstrakter og antineoplastiske forbindelser
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
EA200200922A1 (ru) Композиция, включающая камптотецин и производное пиримидина, для лечения рака
SE9802208D0 (sv) Novel compounds
NO20031860D0 (no) Kahalaolid F
DK1294372T3 (da) Törpulverformulering der omdanner racecadotril
NO20031673D0 (no) Behandling av kreft
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
ATE275143T1 (de) Verbindungen
IS6574A (is) Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
SE9802209D0 (sv) Novel compounds
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
BR0111785A (pt) Composições e métodos para tratamento de candidìase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application